United States Food and Drug Administration (USFDA) has concluded routine current Good Manufacturing Practices (cGMP) inspection at Cipla’s manufacturing facility located in Patalganga, Maharashtra, India from March 28, 2024 to April 4, 2024.
On conclusion of the inspection, the company has received 6 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within the stipulated time.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
